vs
Side-by-side financial comparison of BayCom Corp (BCML) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $20.6M, roughly 1.3× Entrada Therapeutics, Inc.). BayCom Corp runs the higher net margin — 26.5% vs -84.4%, a 110.9% gap on every dollar of revenue. On growth, BayCom Corp posted the faster year-over-year revenue change (9.4% vs -65.2%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs 2.9%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
BCML vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $20.6M |
| Net Profit | $6.9M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | 36.6% | -106.0% |
| Net Margin | 26.5% | -84.4% |
| Revenue YoY | 9.4% | -65.2% |
| Net Profit YoY | 12.1% | -173.8% |
| EPS (diluted) | $0.63 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | — | ||
| Q3 25 | $25.7M | — | ||
| Q2 25 | $24.7M | — | ||
| Q1 25 | $24.3M | $20.6M | ||
| Q4 24 | $23.7M | $37.4M | ||
| Q3 24 | $25.6M | $19.6M | ||
| Q2 24 | $23.8M | $94.7M | ||
| Q1 24 | $24.5M | $59.1M |
| Q4 25 | $6.9M | — | ||
| Q3 25 | $5.0M | — | ||
| Q2 25 | $6.4M | — | ||
| Q1 25 | $5.7M | $-17.3M | ||
| Q4 24 | $6.1M | $1.1M | ||
| Q3 24 | $6.0M | $-14.0M | ||
| Q2 24 | $5.6M | $55.0M | ||
| Q1 24 | $5.9M | $23.5M |
| Q4 25 | 36.6% | — | ||
| Q3 25 | 26.3% | — | ||
| Q2 25 | 35.3% | — | ||
| Q1 25 | 31.6% | -106.0% | ||
| Q4 24 | 34.2% | -15.7% | ||
| Q3 24 | 32.4% | -110.7% | ||
| Q2 24 | 31.9% | 56.4% | ||
| Q1 24 | 33.3% | 35.7% |
| Q4 25 | 26.5% | — | ||
| Q3 25 | 19.5% | — | ||
| Q2 25 | 25.8% | — | ||
| Q1 25 | 23.4% | -84.4% | ||
| Q4 24 | 25.9% | 3.0% | ||
| Q3 24 | 23.5% | -71.7% | ||
| Q2 24 | 23.6% | 58.1% | ||
| Q1 24 | 24.0% | 39.7% |
| Q4 25 | $0.63 | — | ||
| Q3 25 | $0.46 | — | ||
| Q2 25 | $0.58 | — | ||
| Q1 25 | $0.51 | $-0.42 | ||
| Q4 24 | $0.55 | $-0.20 | ||
| Q3 24 | $0.54 | $-0.35 | ||
| Q2 24 | $0.50 | $1.55 | ||
| Q1 24 | $0.51 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.6M | $417.3M |
| Total Assets | $2.6B | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $67.8M | ||
| Q4 24 | — | $101.2M | ||
| Q3 24 | — | $78.0M | ||
| Q2 24 | — | $185.3M | ||
| Q1 24 | — | $68.4M |
| Q4 25 | $338.6M | — | ||
| Q3 25 | $334.3M | — | ||
| Q2 25 | $330.6M | — | ||
| Q1 25 | $329.3M | $417.3M | ||
| Q4 24 | $324.4M | $428.7M | ||
| Q3 24 | $321.7M | $422.4M | ||
| Q2 24 | $315.3M | $429.9M | ||
| Q1 24 | $314.2M | $269.4M |
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.6B | $486.5M | ||
| Q4 24 | $2.7B | $526.3M | ||
| Q3 24 | $2.6B | $554.6M | ||
| Q2 24 | $2.6B | $582.0M | ||
| Q1 24 | $2.6B | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $-38.5M |
| Free Cash FlowOCF − Capex | $30.1M | $-39.7M |
| FCF MarginFCF / Revenue | 116.2% | -192.9% |
| Capex IntensityCapex / Revenue | 6.7% | 5.6% |
| Cash ConversionOCF / Net Profit | 4.64× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | — | ||
| Q3 25 | $7.3M | — | ||
| Q2 25 | $6.4M | — | ||
| Q1 25 | $9.3M | $-38.5M | ||
| Q4 24 | $30.4M | $-31.6M | ||
| Q3 24 | $9.6M | $-24.3M | ||
| Q2 24 | $7.7M | $39.8M | ||
| Q1 24 | $5.1M | $-25.5M |
| Q4 25 | $30.1M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $5.6M | — | ||
| Q1 25 | $9.1M | $-39.7M | ||
| Q4 24 | $28.7M | $-32.2M | ||
| Q3 24 | $9.4M | $-24.9M | ||
| Q2 24 | $7.4M | $38.8M | ||
| Q1 24 | $3.9M | $-26.4M |
| Q4 25 | 116.2% | — | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | 22.8% | — | ||
| Q1 25 | 37.6% | -192.9% | ||
| Q4 24 | 121.1% | -86.2% | ||
| Q3 24 | 36.6% | -127.3% | ||
| Q2 24 | 31.2% | 41.0% | ||
| Q1 24 | 16.1% | -44.6% |
| Q4 25 | 6.7% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 3.0% | — | ||
| Q1 25 | 0.6% | 5.6% | ||
| Q4 24 | 7.2% | 1.7% | ||
| Q3 24 | 1.0% | 3.3% | ||
| Q2 24 | 1.0% | 1.1% | ||
| Q1 24 | 4.7% | 1.4% |
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | -27.94× | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | 0.72× | ||
| Q1 24 | 0.86× | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
